email@email.com
Request a Call
Contact Online
Subscribe |
| Log In
The most widely read newsletter on China's life science industry.
Toggle navigation
Home
Subscribe
Top Stories
Hot Topics
Search
Conferences
Consulting
About Us
Contact Us
You are here:
All Products
Articles
Instant access to selected
ChinaBio® Today
subscriber-only articles.
Browse
All Products
Articles
Viewing
1636 - 1650
of 3612 products
View All
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
Next
Two China Biopharmas Strike $65 Million Deal for Rights to Cell Therapy
$5.00
Available
Corvus Forms $106 Million China Subsidiary with China Rights to Four of its Assets
$5.00
Available
Harbour Bio Starts China Trial of Autoimmune Treatment
$5.00
Available
CARsgen Granted US Orphan Drug Status for Claudin18.2 CAR-T Drug
$5.00
Available
I-Mab to Start China Phase III Trial of Long-Acting Treatment for Dwarfism
$5.00
Available
Virogin Raises $62 Million for Oncolytic Virus Portfolio
$5.00
Available
Sumgen Completes $32 Million Round for Immunotherapy Antibodies
$5.00
Available
CStone Out-licenses China Rights for PD-1 to Pfizer in $480 Million Deal
$5.00
Available
Fosun Closes $182 Million In-licensing of Polyphor Cancer Treatment
$5.00
Available
Apollomics to Start China Trials of In-Licensed Leukemia Drug
$5.00
Available
Taimei Tech Completes $176 Million Raise for AI Clinical Trial Software
$5.00
Available
BioShin Raises $60 Million to Bring Biohaven's Drugs to China
$5.00
Available
Junshi Says its PD-1 Effective Against Nasopharyngeal Carcinoma
$5.00
Available
Zai Lab Raises $761 Million in Hong Kong IPO; Climbs 8.5% Higher
$5.00
Available
InventisBio Completes $147 Million Round for Small-Molecule Drugs
$5.00
Available